{
  "study_id": "NCT05351541",
  "agent": "baseline",
  "run": 4,
  "p_primary_hypothesis_supported": 0.8,
  "effect_direction": "favours intervention",
  "effect_size_90pct_interval": {"low": 3, "high": 20, "metric": "Mean change in BPI interference, 0-70 scale, baseline to 1 month (positive = reduction)"},
  "moderator_prediction": "none detectable; with ~30 participants split over four add-on arms (~7 each) no reliable difference is expected. If any trend, zolpidem arms may show slightly smaller reductions (sedation blunting the acute experience/memory) and modafinil arms no different from placebo.",
  "claim_ids_used": [],
  "rationale": "Resolution is effectively a pooled pre-post test: every participant gets psilocybin with therapy, the outcome is self-reported, participants are unblinded to psilocybin effects, and regression to the mean plus expectancy in treatment-refractory chronic pain usually produce significant within-group improvement (primer 1.6: single-arm pre-post symptom outcomes are significant >90% of the time). Offsets: n~30 with dropout, chronic pain expectation effects are smaller, single-dose effects fade by 1 month, variable dose (1-30 mg) may dilute, and the report might emphasise between-arm comparisons or not report a pooled test. Expected reduction roughly 8-12 points from a baseline near 30-40."
}